Rodríguez-Jiménez P, Chicharro P, Reymundo A, Fernández-Bernáldez A, Navarro R, Sánchez-Pérez J

Language: Spanish
References: 15
Page: 39-42
PDF size: 225.52 Kb.

ABSTRACT

Introduction: Chronic hand eczema (CHE) affects between 5 and 7% of the population. The purpose of the article is to describe the use of oral alitretinoin in patients with refractory in our centre and to carry out a literature review up to date. Material and methods: Cross-sectional descriptive retrospective observational study, based on the retrospective review of clinical records of patients with CHE treated with alitretinoin. Results: We reviewed eight records from patients treated with alitretinoin. A dose of 30 mg/day was used in all patients, after which 75% of the patients achieved a satisfactory clinical response. The adverse events were all predictable and mild and did not require the suspension of treatment in any case. Conclusion: The results show a high efficacy for the treatment of CHE with oral alitretinoin according to what has been published up to date in the literature and the recommendations established in the clinical practice guidelines. We have to remark the good response to treatment in our series and the few adverse effects.

REFERENCES

1. Diepgen TL, Andersen KE, Chosidow O et al. Guidelines for diagnosis, prevention and treatment of hand eczema. J Dtsch Dermatol Ges. 2015; 13 (1): e1-22.

2. Ficha técnica Toctino(reg). 09/2015 GSK.

3. Blair HA, Scott LJ. Alitretinoin: a review in severe chronic hand eczema. Drugs. 2016; 76: 1271-1279.

4. Diepgen TL, Agner T, Aberer W et al. Management of chronic hand eczema. Contact Dermat. 2007; 57 (4): 203-210.

5. Ruzicka T, Larsen FG, Galewicz D, Horváth A, Coenraads PJ, Thestrup-Pedersen K et al. Oral alitretinoin (9-cis-retinoic acid) therapy for chronic hand dermatitis in patients refractory to standard therapy: results of a randomized, double-blind, placebo-controlled, multicenter trial. Arch Dermatol. 2004; 140 (12): 1453-1459.

6. Ruzicka T, Lynde CW, Jemec GB et al. Efficacy and safety of oral alitretinoin (9-cisretinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial. Br J Dermatol. 2008; 158 (4): 808-817.

7. Aguayo-Leiva IR, Urrutia S, Jaén-Olasolo P. Respuesta al tratamiento con alitretinoína oral en ECM refractario con eczema crónico de manos refractario al tratamiento con corticoides tópicos potentes: nuestra experiencia en 15 pacientes. Actas Dermosifiliogr. 2011; 102 (8): 616-622.

8. Bissonnette R, Worm M, Gerlach B et al. Successful retreatment with alitretinoin in patients with relapsed chronic hand eczema. Br J Dermatol. 2010; 162 (2): 420-426.

9. Dirschka T, Reich K, Bissonnette R, Maares J, Brown T, Diepgen TL. An open-label study assessing the safety and efficacy of alitretinoin in patients with severe chronic hand eczema unresponsive to topical corticosteroids. Clin Exp Dermatol. 2011; 36 (2): 149-154.

10. Schmitt-Hoffmann AH, Roos B, Sauer J, Spickermann J, Stoeckel K, Edwards D et al. Pharmacokinetics, efficacy and safety of alitretinoin in moderate or severe chronic hand eczema. Clin Exp Dermatol. 2011; 36 Suppl 2: 29-34.

11. Lynde C, Cambazard F, Ruzicka T et al. Extended treatment with oral alitretinoin for patients with chronic hand eczema not fully responding to initial treatment. Clin Exp Dermatol. 2012; 37 (7): 712-717.

12. Diepgen TL, Pfarr E, Zimmermann T. Efficacy and tolerability of alitretinoin for chronic hand eczema under daily practice conditions: results of the TOCCATA open study comprising 680 patients. Acta Derm Venereol. 2012; 92 (3): 251-255.

13. Fowler JF, Graff O, Hamedani AG. A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of alitretinoin (BAL4079) in the treatment of severe chronic hand eczema refractory to potent topical corticosteroid therapy. J Drugs Dermatol. 2014; 13 (10): 1198-1204.

14. Politiek K, Christofers WA, Coenraads PJ et al. Alitretinoin and acitretin in severe chronic hand eczema; results from a retrospective daily practice study. Dermatol Ther. 2016; 29 (5): 364-371.

15. Blank PR, Blank AA, Szucs TD. Cost-effectiveness of oral alitretinoin in patients with severe chronic hand eczema--a long-term analysis from a Swiss perspective. BMC Dermatol. 2010; 10: 4.